BTM-3566
Mature B-cell Lymphomas (DLBCL, MCL, FL)
Pre-clinicalActive
Key Facts
Indication
Mature B-cell Lymphomas (DLBCL, MCL, FL)
Phase
Pre-clinical
Status
Active
Company
About Bantam Pharmaceutical
Bantam Pharmaceutical is an early-stage oncology biotech pioneering a novel approach to cancer treatment by targeting mitochondrial homeostasis to induce cancer cell death. Founded in 2018 and based in Cambridge, MA, the company is advancing its lead candidate, BTM-3566, towards Phase 1 trials for B-cell lymphomas, with plans to expand into solid tumors. Bantam operates with a capital-efficient model, has raised funding, and is led by a team with extensive oncology drug development experience. The company represents an early mover in the emerging field of mitochondrial-targeted cancer therapies.
View full company profile